168 related articles for article (PubMed ID: 24152827)
1. The dual Aurora kinase inhibitor ZM447439 prevents anaplastic thyroid cancer cell growth and tumorigenicity.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Catania A; Moretti C; Mocini R; Carbotta G; Morrone S; Persechino S; Redler A; De Antoni E; D' Armiento M; Ulisse S
J Biol Regul Homeost Agents; 2013; 27(3):705-15. PubMed ID: 24152827
[TBL] [Abstract][Full Text] [Related]
2. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
[TBL] [Abstract][Full Text] [Related]
3. Effects of the Aurora kinases pan-inhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines.
Baldini E; Sorrenti S; D'Armiento E; Guaitoli E; Morrone S; D'Andrea V; Gnessi L; Moretti C; Antonelli A; Catania A; De Antoni E; Ulisse S
Clin Ter; 2012; 163(5):e307-13. PubMed ID: 23099978
[TBL] [Abstract][Full Text] [Related]
4. ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin.
Zhang L; Zhang S
J Obstet Gynaecol Res; 2011 Jun; 37(6):591-600. PubMed ID: 21159048
[TBL] [Abstract][Full Text] [Related]
5. Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines.
Arlot-Bonnemains Y; Baldini E; Martin B; Delcros JG; Toller M; Curcio F; Ambesi-Impiombato FS; D'Armiento M; Ulisse S
Endocr Relat Cancer; 2008 Jun; 15(2):559-68. PubMed ID: 18430894
[TBL] [Abstract][Full Text] [Related]
6. Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line.
Tuccilli C; Baldini E; Prinzi N; Morrone S; Sorrenti S; Filippini A; Catania A; Alessandrini S; Rendina R; Coccaro C; D'Armiento M; Ulisse S
Endocrine; 2016 May; 52(2):287-95. PubMed ID: 26215279
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer.
Wunderlich A; Fischer M; Schlosshauer T; Ramaswamy A; Greene BH; Brendel C; Doll D; Bartsch D; Hoffmann S
Cancer Sci; 2011 Apr; 102(4):762-8. PubMed ID: 21214672
[TBL] [Abstract][Full Text] [Related]
8. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947.
Libertini S; Abagnale A; Passaro C; Botta G; Barbato S; Chieffi P; Portella G
Endocr Relat Cancer; 2011 Feb; 18(1):129-41. PubMed ID: 21071467
[TBL] [Abstract][Full Text] [Related]
9. A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity.
Li J; Hu H; Lang Q; Zhang H; Huang Q; Wu Y; Yu L
Eur J Med Chem; 2013 Jul; 65():151-7. PubMed ID: 23707920
[TBL] [Abstract][Full Text] [Related]
10. ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines.
Georgieva I; Koychev D; Wang Y; Holstein J; Hopfenmüller W; Zeitz M; Grabowski P
Neuroendocrinology; 2010; 91(2):121-30. PubMed ID: 19923785
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 4-aminoquinazoline--urea derivatives as Aurora kinase inhibitors with antiproliferative activity.
Cai J; Li L; Hong KH; Wu X; Chen J; Wang P; Cao M; Zong X; Ji M
Bioorg Med Chem; 2014 Nov; 22(21):5813-23. PubMed ID: 25270403
[TBL] [Abstract][Full Text] [Related]
12. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts.
Walsby E; Walsh V; Pepper C; Burnett A; Mills K
Haematologica; 2008 May; 93(5):662-9. PubMed ID: 18367484
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative effect of Aurora kinase targeting in mesothelioma.
Crispi S; Fagliarone C; Biroccio A; D'Angelo C; Galati R; Sacchi A; Vincenzi B; Baldi A; Verdina A
Lung Cancer; 2010 Dec; 70(3):271-9. PubMed ID: 20371132
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibitors of aurora kinases inhibit proliferation, reduce cell viability and impair cell cycle progression in papillary thyroid carcinoma cells.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Fallahi P; Mian C; Barollo S; Catania A; Morrone S; Tartaglia F; Mascagni D; Coccaro C; Pepe M; Filippini A; D'Armiento M; Ulisse S
J Biol Regul Homeost Agents; 2015; 29(4):793-803. PubMed ID: 26753639
[TBL] [Abstract][Full Text] [Related]
15. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores.
Ditchfield C; Johnson VL; Tighe A; Ellston R; Haworth C; Johnson T; Mortlock A; Keen N; Taylor SS
J Cell Biol; 2003 Apr; 161(2):267-80. PubMed ID: 12719470
[TBL] [Abstract][Full Text] [Related]
16. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.
Kalous O; Conklin D; Desai AJ; Dering J; Goldstein J; Ginther C; Anderson L; Lu M; Kolarova T; Eckardt MA; Langerød A; Børresen-Dale AL; Slamon DJ; Finn RS
Breast Cancer Res Treat; 2013 Oct; 141(3):397-408. PubMed ID: 24091768
[TBL] [Abstract][Full Text] [Related]
17. p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases.
Marxer M; Ma HT; Man WY; Poon RY
Oncogene; 2014 Jul; 33(27):3550-60. PubMed ID: 23955083
[TBL] [Abstract][Full Text] [Related]
18. Combination Treatment of OSI-906 with Aurora B Inhibitor Reduces Cell Viability via Cyclin B1 Degradation-Induced Mitotic Slippage.
Ikeda Y; Yasutake R; Yuki R; Saito Y; Nakayama Y
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071893
[TBL] [Abstract][Full Text] [Related]
19. Trivalent dimethylarsenic compound induces histone H3 phosphorylation and abnormal localization of Aurora B kinase in HepG2 cells.
Suzuki T; Miyazaki K; Kita K; Ochi T
Toxicol Appl Pharmacol; 2009 Dec; 241(3):275-82. PubMed ID: 19716834
[TBL] [Abstract][Full Text] [Related]
20. Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.
Nappi TC; Salerno P; Zitzelsberger H; Carlomagno F; Salvatore G; Santoro M
Cancer Res; 2009 Mar; 69(5):1916-23. PubMed ID: 19223553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]